R De Wit
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
van Soest R, Tannock I, Eisenberger M, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F, Templeton A, De Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†. Ann Oncol 2014
15.12.2014Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
15.12.2014Ann Oncol 2014
van Soest R J, Tannock I F, Eisenberger M A, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F E, Templeton Arnoud, De Wit R
Personalizing, not patronizing: The case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
Oldenburg J, Gillessen Sommer S, Haugnes H, Honecker F, Horwich A, Lorch A, Ondruscaron D, Rosti G, Stephenson A, Germà-Lluch J, Fossa S, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, De Wit R, Tandstad T. Personalizing, not patronizing: The case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 2014
06.11.2014Personalizing, not patronizing: The case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
06.11.2014Ann Oncol 2014
Oldenburg J, Gillessen Sommer Silke, Haugnes H S, Honecker F, Horwich A, Lorch A, Ondruscaron D, Rosti G, Stephenson A, Germà-Lluch J R, Fossa S D, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, De Wit R, Tandstad T
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J, Lorch A, Looijenga L, Laguna M, Krege S, Kollmannsberger C, Kliesch S, Huddart R, Oechsle K, Oldenburg J, Oosterhuis J, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A, Cohn-Cedermark G, Classen J, Clarke N, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J, Giwercman A, Gillessen S, Gietema J, Germá Lluch J, Fossa S, Fléchon A, Fizazi K, Fenner M, Dieckmann K, De Wit R, Beyer J. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2012; 24:878-88.
14.11.2012Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
14.11.2012Ann Oncol 2012; 24:878-88
Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J P, Lorch A, Looijenga L H J, Laguna M P, Krege S, Kollmannsberger C, Kliesch S, Huddart R A, Oechsle K, Oldenburg J, Oosterhuis J W, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A A, Cohn-Cedermark G, Classen J, Clarke N W, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J T, Giwercman A, Gillessen S, Gietema J A, Germá Lluch J R, Fossa S D, Fléchon A, Fizazi K, Fenner M, Dieckmann K P, De Wit R, Beyer J